Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

about

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.Effectiveness of alternative dose fingolimod for multiple sclerosis.

P2860

Q38606914-25DB78FB-3255-41C4-862D-514E3D52440B Q52677983-D85CDA16-F6B3-4521-8C09-0AF45139F5BB Q54225321-FE790F37-882F-4D46-BDB7-F81E70AE1FD5

P2860

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

Item

http://www.wikidata.org/entity/Q38920498

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Half-dose fingolimod for treat ...... clerosis: Observational study.

@en

type

Item

label

Half-dose fingolimod for treat ...... clerosis: Observational study.

@en

prefLabel

Half-dose fingolimod for treat ...... clerosis: Observational study.

@en

P1476

Half-dose fingolimod for treat ...... clerosis: Observational study.

@en

P2093

Arianna Merlini

http://www.w3.org/2001/XMLSchema#string

Catia Stefanin

http://www.w3.org/2001/XMLSchema#string

Chiara Zecca

http://www.w3.org/2001/XMLSchema#string

Claudio Gobbi

http://www.w3.org/2001/XMLSchema#string

Emanuele Pravatà

http://www.w3.org/2001/XMLSchema#string

Francesco Patti

http://www.w3.org/2001/XMLSchema#string

Giulio Disanto

http://www.w3.org/2001/XMLSchema#string

Letizia Panicari

http://www.w3.org/2001/XMLSchema#string

Lucia Moiola

http://www.w3.org/2001/XMLSchema#string

Maria Josè Messina

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Invited commentary: propensity scores.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Clinical pharmacokinetics of fingolimod.

Can we measure long-term treatment effects in multiple sclerosis?

Disease activity return after natalizumab cessation in multiple sclerosis.

P304

1352458517694089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458517694089

http://www.w3.org/2001/XMLSchema#string

P50

Alessio Ghezzi

Giancarlo Comi

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28273776

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

about

P2860

P2860

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P921